

Healthy Volunteers

A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT04023994 BP41192

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

Study BP41192 is a randomized, adaptive, placebo-controlled parallel group study to investigate the safety, tolerability, immunogenicity and pharmacokinetics of single-ascending intravenous (IV) doses of RO7126209 in healthy participants. RO7126209 is being developed for the treatment of Alzheimer's Disease.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT04023994 BP41192
Trial Identifiers

Eligibility Criteria:

Gender
Male

Age
≥18 Years & ≤ 40 Years

Healthy Volunteers
Accepts Healthy Volunteers
